Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer.
Chemistry
; 26(63): 14335-14340, 2020 Nov 11.
Article
en En
| MEDLINE
| ID: mdl-32738078
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells and found to be 4â
times more cytotoxic than sunitinib and 1.7â
times more effective than 10 B-boronophenylalanine fructose complex when the cells were irradiated with neutrons.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Preparaciones Farmacéuticas
/
Supervivencia Celular
/
Terapia por Captura de Neutrón de Boro
/
Glioblastoma
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Chemistry
Asunto de la revista:
QUIMICA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Uruguay
Pais de publicación:
Alemania